预约演示
更新于：2025-12-22
Sacubitril/Valsartan
沙库巴曲缬沙坦钠
更新于：2025-12-22
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2015-07-07), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C48H61N6NaO9 |
InChIKeyBHNNEXLQFVQGSE-LWRBNZNASA-N |
CAS号936623-90-4 |
关联
402
项与 沙库巴曲缬沙坦钠 相关的临床试验NCT06704633
Health Status After Switching Angiotensin-converting Enzyme Inhibitors or Angiotensin Receptor Blockers to Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania: An Interventional Study
IRCT20180620040164N96
Comparative bioequivalence study of Sacubitril Valsartan 50 mg Tablet of Cosar Pharmaceutical Co. and Entresto® of Novartis in 24 healthy subjects under fasting condition
NCT07192341
Effect of Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction
100 项与 沙库巴曲缬沙坦钠 相关的临床结果
登录后查看更多信息
100 项与 沙库巴曲缬沙坦钠 相关的转化医学
登录后查看更多信息
100 项与 沙库巴曲缬沙坦钠 相关的专利（医药）
登录后查看更多信息
694
项与 沙库巴曲缬沙坦钠 相关的文献（医药）2026-02-01NEUROPHARMACOLOGY
The enhanced Wnt/β-catenin pathway upregulation by sacubitril/valsartan via neprilysin inhibition compared to valsartan in the rotenone induced Parkinson's disease rat model
Article
作者: Nofal, Shahira ; Awny, Magdy M. ; El-Sayed, Elsayed K. ; Awny, Magdy M ; Elkhial, Rania Tarek
Parkinson's disease (PD), the second most common neurodegenerative disorder, is characterized by the progressive loss of dopaminergic neurons in the basal ganglia, particularly in the substantia nigra, and the accumulation of α-synuclein into Lewy bodies. Recently, the WNT/β-catenin signaling pathway has emerged as a potential neuroprotective mechanism in PD, activated by natriuretic peptides (NPs) such as ANP, BNP, and CNP. Sacubitril/valsartan (SAC/VAL) is an FDA-approved medication for chronic heart failure. SAC contains neprilysin inhibition, while VAL is an angiotensin receptor blocker used to treat hypertension. This study aimed to determine whether SAC/VAL could activate the WNT/β-catenin pathway by increasing NP levels. To isolate the effect of SAC, VAL was administered separately. Male Wistar rats were injected with 2 mg/kg rotenone subcutaneously (S.C.) for 35 days to induce a PD-like model. VAL and SAC/VAL were administered orally at 20 mg/kg/day and 40 mg/kg/day, respectively, one week before rotenone treatment for six weeks. SAC/VAL was more effective than VAL in reducing rotenone-induced behavioral deficits, mitigating dopaminergic injury, normalizing dopamine (DA), tyrosine hydroxylase (TH), and NP levels, and activating the WNT/β-catenin pathway. SAC/VAL also suppressed oxidative stress and neuroinflammation. In conclusion, SAC/VAL exhibited greater neuroprotection against PD-induced neurodegeneration than VAL, likely due to neprilysin inhibition by the SAC component, which activates the WNT/β-catenin pathway.
2026-01-01WATER RESEARCH
Lanthanum-quaternized chitosan-modified zeolite for long-lasting operation of constructed wetland: A bifunctional strategy for simultaneous phosphorus removal and microbial clogging mitigation
Article
作者: Wang, Hao-Yu ; Sha, Hong-Yin ; Lu, Yong-Ze ; Zhang, Jian-Guo ; Zhu, Guang-Can ; Wang, Yi-Ru ; Wang, Ling
Saturation adsorption capacity and clogging pose persistent challenges to phosphorus (P) removal in constructed wetlands. Developing substrates capable of efficient and sustained P sequestration is therefore critical. However, few existing substrates achieve both high performance and long-term stability. Here, we report a novel engineered substrate, Lanthanum-quaternized chitosan modified zeolite (LCZ), synthesized from natural zeolite via an impregnation method. LCZ exhibits a maximum phosphate adsorption capacity of 46.69 ± 0.93 mg/g in a 100 mg P/L solution-representing a 16-fold enhancement over pristine zeolite (2.89 ± 0.01 mg/g). The adsorption mechanism involves synergistic effects of electrostatic attraction, ligand/ion exchange, and surface precipitation. Notably, the synergistic action of lanthanum and quaternized chitosan imparts LCZ with potent antibacterial properties, significantly reducing bacterial adhesion compared to natural zeolite. Granulation with cement yields the wetland substrate LCZ-C, which features a porous surface morphology with sharp-edged, nanoflower-like architectures. These architectures, with their ultra-high surface area, are highly effective for phosphorus fixation, enhancing P availability. Concurrently, the inherent sharp edges of these nanomaterials provide a powerful physical mechanism for antibacterial activity, mechanically disrupting pathogenic bacterial cell membranes. LCZ-C effectively reduced P levels in actual lake water to consistently below 0.05 mg/L, and the removal efficiency was close to 80 %. Hedley sequential P fractionation revealed that HCl-extractable P, representing a stable P pool, constitutes the dominant fraction (67.64 %) of the adsorbed P, indicating superior long-term P immobilization potential in eutrophic waters. Crucially, coculture experiments demonstrated that LCZ-C could efficiently kill Escherichia coli through the "breaking-cell-wall" effect, which disrupts bacterial cells on its surface and exerts durable antibacterial effects. This translates to significant resistance to biofilm formation, suggesting a potential solution to mitigate substrate clogging. This work offers a sustainable solution that ensures stable, long-term performance in enhanced phosphorus removal within constructed wetlands.
2025-12-01JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
Development of a pseudotargeted metabolomics approach for relative quantification of free fatty acid double-bond isomers in beagle plasma
Article
作者: Zhang, Zunjian ; Xiao, Wen ; Tian, Yuan ; Liu, Qiaorong ; Han, Jiameng ; Ren, Haihui ; Zhang, Yueyi
Free fatty acids (FFAs) play a key role in living organisms and participate in metabolic processes, mainly as a source of energy for cells. The CC position isomer of FFAs is strongly associated with many diseases, but quantification of its double bond position isomer remains a challenge in lipid analysis. In this study, based on the requirements of the pseudotargeted metabolomics, an analytical method based on a two-step derivatization LC-MS/MS method and a multiple reaction monitoring (MRM) mode was established and fully validated in terms of linearity, precision, and stability. The results demonstrated that the method relatively quantified 30 FFAs in plasma samples. These included 8 saturated fatty acids (SFAs), 12 monounsaturated fatty acids (MUFAs), and 10 polyunsaturated fatty acids (PUFAs). The developed method was applied to analyze the increase or down-regulation of the relative content of FFAs before and after the administration of the drug in beagles which may help to explain the therapeutic effect of sacubitril valsartan. The establishment of this method allows the study of FFAs in beagles plasma to be no longer limited to analysis at the subclass level but can be focused at the isomer level.
100 项与 沙库巴曲缬沙坦钠 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 原发性高血压 | 中国 | 2021-05-24 | |
| 高血压 | 日本 | 2020-06-29 | |
| 左心室收缩功能障碍 | 美国 | 2019-10-01 | |
| 射血分数降低的慢性心力衰竭 | 欧盟 | 2015-11-19 | |
| 射血分数降低的慢性心力衰竭 | 冰岛 | 2015-11-19 | |
| 射血分数降低的慢性心力衰竭 | 列支敦士登 | 2015-11-19 | |
| 射血分数降低的慢性心力衰竭 | 挪威 | 2015-11-19 | |
| 心脏衰竭 | 瑞士 | 2015-09-17 | |
| 慢性心力衰竭 | 美国 | 2015-07-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 心肌梗塞后综合征 | 临床3期 | - | 2021-05-26 | |
| 勃起功能障碍 | 临床3期 | 德国 | 2019-04-16 | |
| 收缩性心力衰竭 | 临床3期 | 德国 | 2019-04-16 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2016-12-09 | |
| 急性心肌梗塞 | 临床3期 | 中国 | 2016-12-09 | |
| 急性心肌梗塞 | 临床3期 | 阿根廷 | 2016-12-09 | |
| 急性心肌梗塞 | 临床3期 | 澳大利亚 | 2016-12-09 | |
| 急性心肌梗塞 | 临床3期 | 奥地利 | 2016-12-09 | |
| 急性心肌梗塞 | 临床3期 | 比利时 | 2016-12-09 | |
| 急性心肌梗塞 | 临床3期 | 巴西 | 2016-12-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 922 | 獵鑰網膚選顧蓋鹹製鹹(鏇醖壓襯構積鏇壓鹹願) = 願餘窪蓋鏇鹽艱窪齋繭 繭衊鬱壓醖鑰願網構築 (醖簾範醖觸襯繭鹹繭艱 ) 更多 | 不佳 | 2025-12-03 | |||
獵鑰網膚選顧蓋鹹製鹹(鏇醖壓襯構積鏇壓鹹願) = 積遞醖餘網鹹築糧築窪 繭衊鬱壓醖鑰願網構築 (醖簾範醖觸襯繭鹹繭艱 ) 更多 | |||||||
临床3期 | 12,974 | 壓襯壓壓壓鹽壓積選構(網構艱窪壓網願範簾願): OR = 1.16 (95.0% CI, 1.08 ~ 1.24) 更多 | 积极 | 2025-11-04 | |||
临床3期 | 心脏衰竭 NT-proBNP | LVEF | 847 | 憲築築糧憲簾衊夢積鏇(襯獵糧網壓願鹹糧獵遞): rate ratio = 0.6 (95% CI, 0.37 ~ 0.99), P-Value = 0.046 更多 | 积极 | 2025-11-01 | ||
临床2期 | 138 | 製積衊鹹憲構齋廠膚糧(膚夢製餘廠鏇鹽糧觸觸): Difference = 0.3 (95.0% CI, 0.05 ~ 0.6) 更多 | 不佳 | 2025-10-21 | |||
Placebo | |||||||
临床3期 | 心脏衰竭 amino terminal pro-B type natriuretic peptide (NT-proBNP) | - | 醖簾鑰願蓋艱鹽選壓顧(憲壓觸餘築網齋廠遞顧): ratio of change = 0.85 (95% CI, 0.73 ~ 0.999) | 积极 | 2025-10-01 | ||
临床4期 | 4 | (LCZ696) | 鹽鑰遞齋淵鑰廠鏇餘蓋(鑰艱衊憲範積鹽蓋願襯) = 蓋齋願繭夢窪醖築廠衊 醖鏇鏇願窪繭窪醖糧願 (鏇糧製艱夢觸範積遞獵, 鏇憲繭鹹鹹鹽範繭顧蓋 ~ 憲願餘鏇壓顧襯憲窪膚) | - | 2025-08-03 | ||
(Valsartan) | 鹽鑰遞齋淵鑰廠鏇餘蓋(鑰艱衊憲範積鹽蓋願襯) = 餘壓顧積積廠獵鏇鏇壓 醖鏇鏇願窪繭窪醖糧願 (鏇糧製艱夢觸範積遞獵, 遞鹽鑰憲鑰鏇觸夢築糧 ~ 鑰淵齋積鏇蓋憲醖鹽構) 更多 | ||||||
临床3期 | 心脏衰竭 N-terminal pro-B type natriuretic peptide (NT-proBNP) | - | 獵艱繭壓夢網蓋範廠簾(衊膚積製蓋選夢憲選鑰) = 顧衊繭艱憲鹽壓製觸獵 選鑰築願範艱構遞積顧 (壓鑰艱構繭構窪築窪餘, 5.3 ~ 6.5) | 积极 | 2025-06-01 | ||
临床3期 | 8,399 | 獵繭鑰繭繭遞餘膚積壓(蓋繭膚壓夢齋鏇糧積簾): P-Value = 0.62 更多 | 积极 | 2025-05-06 | |||
临床3期 | 心脏衰竭 N-terminal pro-B-type natriuretic peptide (NT-proBNP) | 466 | 鬱選窪製膚餘鹽遞壓網(鏇夢繭夢顧製蓋艱鏇衊) = 窪鑰願鏇夢簾膚觸鬱繭 糧襯淵齋醖襯蓋膚鏇鏇 (衊鑰艱夢鹹膚獵鬱膚製, 1.04 ~ 1.56) 更多 | 积极 | 2025-02-01 | ||
临床3期 | 12,197 | 艱鬱網夢鑰觸獵襯艱艱(淵選選艱醖餘鹽憲積築) = Rates of severe angioedema were higher with sacubitril/valsartan vs RASi (White: 0.2% vs 0.1%; Black: 1.5% vs 0.0%; Asian: 0.1% vs 0.1%) 願顧顧醖淵繭遞膚願獵 (鬱壓顧蓋壓餘憲窪醖糧 ) | 积极 | 2025-01-01 | |||
RASi (enalapril or valsartan) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用